BARCELONA—Some patients with alcoholic liver disease develop alcoholic hepatitis which eventually results in multiorgan failure and death. End-stage liver disease may lead to acute-on-chronic liver failure (ACLF), a syndrome characterized by acute decompensation of cirrhosis, organ failures, and high short-term mortality. There is no specific treatment for patients with ACLF and management is based on organ support and liver transplantation. The A-TANGO project aims to address unmet clinical needs for patients with ACLF and improve patient survival rates by means of a novel combinatorial therapeutic strategy – G-TAK improves hepatocyte proliferation through granulocyte colony-stimulating factor (G-CSF) and reduces systemic inflammation by repurposing TAK-242, an antagonist of Toll-like receptor 4. A multicenter phase II clinical trial will be conducted to assess the effectiveness and therapeutic benefits of G-TAK.
The A-TANGO project is coordinated by the European Foundation for the Study of Chronic Liver Failure (EF Clif), Spain, and brings together the inventors of G-TAK and owners of the background intellectual property in a consortium constituted by 14 partner organizations in eight European countries.
The A-TANGO kick-off meeting was held online due to current measures against COVID-19. Participants at the meeting presented the framework of activities and strategic plan to achieve main project goals, elected members of the Impact Board, and incorporated valuable feedback from the Scientific and Ethical Advisory Board.
This study received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 945096.
The European Foundation for the Study of Chronic Liver Failure (EF Clif) is a private nonprofit organization which mission is to promote research and education in hepatic chronic failure with the aim to contribute to improving the quality of life and to increase the survival of patients with liver cirrhosis. Since its foundation in 2009, the European Association for the Study of the Liver (EASL) Chair supports research activities through the EASL-Clif Consortium, a network of more than 100 European university hospitals and more than 300 clinical researchers. The Grifols Chair promotes translational studies across centers throughout Europe and North America within the framework of the European Network for Translational Research (ENTR) with 25 centers and more than 40 investigators.